Extensive-stage small-cell lung cancer: new approaches on the horizon?
Tarlatamab as first-line therapy and ceralasertib plus durvalumab as maintenance therapy have demonstrated potential efficacy and manageable tolerability
Local consolidative therapy combined with osimertinib improves progression-free survival in metastatic EGFR-mutant NSCLC
Results from the NorthStar trial highlight the potential for integrating local therapy with targeted agents to extend disease control in this setting
International collaboration and a shared vision are key to improving cancer patients’ lives
The 2025 ESMO Lifetime Achievement Awardee, Prof. Rolf Stahel, reflects on the role of the oncology community to drive progress in cancer care
Target-led treatments for lung cancer – are they moving to the next level?
Antibody–drug conjugates may represent a step up from existing therapeutic options, but further optimisation and biomarker analyses are required.
Advancing perioperative treatment in resectable non-small cell lung cancer
Findings from the NeoADAURA and the CheckMate 816 provide novel insights on the role of neoadjuvant osimertinib and nivolumab in the perioperative setting
New evidence is reshaping second-line and maintenance treatment for small cell lung cancer
Two studies investigating efficacy of bispecific T-cell engager tarlatamab and lurbinectedin–atezolizumab combination met their primary endpoints of survival
Perioperative durvalumab led to encouraging survival data in resectable NSCLC
An improvement was observed when immunotherapy was added to neoadjuvant chemotherapy, but further data are needed to confirm the survival benefit
Overall survival benefit achieved with amivantamab plus lazertinib in advanced EGFR-mutated NSCLC
Final results from the MARIPOSA trial provide further supporting evidence to the first-line treatment combination
Drug de-escalation in lung cancer: are we nearly there yet?
While strategies for drug de-escalation continue to be actively pursued, some challenges including insufficient funding of research still limit their applicability
Targeting KRAS G12C in NSCLC: balancing the benefit–risk profile of first-line combinations is still challenging
Studies evaluate the efficacy and safety of promising agents including adagrasib and fulzerasib